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The vaccine industry is turning 
babies into pin-cushions. Ahhough 
some vaccines are combined, there is 
still more than one injection per 
baby, and plenty of screaming in 
pediatric offices. How soothing, then, 
to think of the injection being 
replaced by toothless munching on 
some mashed banana. 
For developing countries, an 
edible vaccine could stop far more 
titan a baby's screaming. If the 
transgenlc plant containing the 
vaccinating material can be grown 
on-site, vaccination logistics could be 
simplified, and costs reduced. 
Several arge companies such as 
Dow and DuPont are moving into 
this area, but it is a small company 
named Axis Genetics, pie 
(Cambridge, UK) that is leading the 
way. The  next few years will be 
crucial for Axis, as it moves beyond 
the promising early science, and into 
the real world of vaccine production. 
First the virus 
The quickest way to make lots of a 
foreign protein in a plant is to infect 
the plant with a virus. Axis started 
with tile cowpea (known in the 
United States as the black-eyed pea) 
and its fast-growing virus CPMV 
(cowpea mosaic virus). The  coat of 
CPMV is derived from the splice- 
and cleavage-products of a single 
gene, and up to 38 amino acids can 
be inserted into a loop of the coat 
protein with no adverse ffects on 
coat assembly. Axis is using this 
system, dubbed Epicoat, for 
vaccines against Pseudomonas 
aeruginosa, Staphylococcus aureus and 
cancer (the latter directed against a
mucin expressed on breast cancer 
cells). 
Epicoat is an alternative to 
peptide vaccines, which were first 
proposed in the 1980s and have 
struggled to establish themselves 
ever since. Axis CEO lain Cubitt 
sees the lack of conformational 
stability in these peptides as a crucial 
fla~; and says that the Axis 
technology solves this by putting the 
peptide in a structured loop. 
Epicoat is a purified injectable, 
bur purified inhalant and nonpurified 
edible forms may follow. Inhaled or 
ingested vaccines encounter the sites 
that are used by most infecting 
pathogens, and these vaccines hould 
induce more effective immunity 
mueosal immunity and secretory IgA 
antibodies, in addition to serum 
antibodies. This approach is not 
practical for peptide vaccines made by 
chemical synthesis because of the 
large amounts of material necessary, 
but the quantity is reasonable for a 
plant-based vaccine. 
if the developing world could grow 
vaccines they could afford them. 
But will edibIe vaccines work? 
But with Epicoat the worst defk:ct 
of peptlde vaccines remains. "Epicoat 
can make a lot of material but you can 
only display a single epitope," says 
Hugh Mason of the Boyce Thompson 
Institute for Plant Research, Inc. 
(BTI; Ithaca, New York). "There is 
not a lot of data so far that single 
epirope vaccines will be very useful." 
With single epitope vaccines, it takes 
but a single mutation for the 
infectious agent o avoid the vaccine- 
induced immunity This has led some 
investigators to string together several 
peptides in the same insertion site, an 
approach that is the subject of an Axis 
patent application. "It is likely that 
several peptides represents a more 
realistic approach than a single 
peptide," says Har~" Greenberg of 
Stanford University (Palo Alto, 
California), who helped develop the 
newly released rotavirus vaccine. 
I say potato,  Dan says potatoe  
If the limiting factor is the amount of 
protein sequence that can be inserted 
in the virus, why not insert the whole 
protein into the plant? This thought, 
or something similar to it, occurred to
Roy Gurtiss and Guy Cardineau 
('vb:ashington |lniversit% St. Louis, 
.Missouri) in 1990, and to Charles 
Arntzen and Mason of B'FI a year 
later. Arntzen and Mason were heavily 
involved in subsequent developments 
in edible vaccine technology.r: In 1998 
Axis concluded eals with both 
lklycogen (San Diego, California), who 
own the Curciss patents, and BTI. 
In the intervening years the plant 
vaccine field Ilad demonstrated the 
successful production of foreign 
proteins in an immunogenJc state 
(1992), the production of antibodies 
in mice fed with plant material 
(1995), protection against disease in 
animals fed plant material (1997), 
and finally the production of 
antibodies in humans fed plant 
material (1998). The latter trials 
invoh,ed the ingestion of "bite-sized 
chunks" of delicious raw potato from 
a plant producing LT-B ~ tile 
binding subunit of a toxin from 
cnterotoxigenic Esc],,erichia call A 
pentamer of LT-B binds gut 
epithelial cells and allows the active 
LT-A toxin subunit o enter the cell. 
The  trial participants ate 50 or 100g 
of raw potato on each of three 
occasions, for a mean of 0.75 mg of 
I:I:B per dose. Ten of 11 showed a 
fourfold rise in serum antibodies, and 
six of 11 showed a fourfold rise in 
secretory (lgA) antibodies. 
Potent ia l  pitfal ls 
The LT-B trials directed by Arntzen 
are encouraging, but no one is 
relaxing yet. "People said edible 
vaccines would never work," says 
Cubitt. "Then when LT-B elicited a 
good response they said of course it 
works because [the bacterium and 
the protein are] normally in the gut. 
For nonenterie diseases it is not so 
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clcar. There  it depends on how we 
present he protein." 
When given orally; a particulate 
virus or even bacterium is efficiently 
sampled by the immune system. 
Although LT-B may be a special case, 
single proteins are usually not 
efficiently taken up. One solution that 
the BTI is working on is to produce 
complete, empty virus-like particles in 
plants simply by expressing the coat 
protein. "~Ve've shown that we can 
produce these structures with 
Norwalk virus in plants," says Mason. 
"The efficiency is questionable and 
variable, but I think it's largely a 
problem with the level of expression." 
Virus-like particles or not, 
expression levels remain a challenge. 
The  solution may be inducible 
expression at a particular time, to 
limit toxicity to the plant. 
The  flip side - -  containing 
expression - - is also a concern. We do 
not make antibodies to all of our food 
because of to le rance-  the damping 
down of the immune system in the 
lace of overwhelming amounts of 
antigen. The  escape of a vaccine plant 
into the general food chain could be a 
disaster if it induced tolerance to a 
major surface protein of a virus. "One 
can't say at this point that it's not a 
possibility," says William Langridge 
(Loma Linda LIniversity, Loma Linda, 
California). "~,Ve hope tAxis] will fund 
further research into this question." 
Langridge stresses, however, that 
tolerance looks to be an unlikely 
No more  fi l l ings 
The alternative to a vaccine is a bolus of 
reac~y-made antibodies. Making 
antibodies in cultured ceils is proNNtiveIy 
expensive, so Julian Ma at Guys Hospital 
in London has turned to plants. 
Ma has tackled Streptococcus 
mutans  - the primary cause of dental 
cavities - with an er.gineered IgA. Two 
tolSical app!ieations a week for three 
weeks eliminated colonization for up to 
four months (published observations) or 
two years (unpublished observations). 
The technology is being commercialized 
by a company from Mountain View, CA, 
called Planet Biotechnology, Inc. 
prospect. I l ls experience stems from 
the successful induction of tolerance 
to a diabetes autoantigen i mice 
(thus preventing further destruction 
of the pancreas). This  was achieved 
with plant material, but only when 
the autoantigen was flJsed to LT-B, 
so that the complex entered gut 
epithelial cells efficientl3: In earlier 
work an unfused autoantigen 
induced tolerance only after two 
months of continuous feeding. 
The  safety issue is particularly 
sensitive following the public uproar 
in Britain over genetically modified 
(GM) foods. This curious incident 
was sparked by one researcher's 
description of his unpublished and 
questionable r sults on a TV show. 
"It's bizarre what has happened in the 
UK," says Cubitt. "Science is being 
ignored in the formation of the public 
perceptinn here." In the United 
States there is an equally distressing 
state of affairs - -  complete apathy - -  
and it is in that country that Axis 
grows its crops (in greenhouses). But 
even in Britain, Cubitt does not 
anticipate any problems. "We are not 
involved because we are in 
pharmaceutical products not food 
products - -  we are already highly 
regulated and not planning to grow 
large areas of crops," he says. "There 
may be a moratorium on growing in 
the field or growing agricultural 
products, but we grow in the US and 
we don't do agriculture. It's nothing to 
do with us." 
Business basics 
Vaccines used to be a treacherous 
business, filled with interminable 
trials with thousands of participants, 
and endless lawsuits from the few of 
the vaccinated millions with an 
;adverse reaction. No more. 
"The  vaccine field has changed 
out of all recognition in the last ten 
years," says Cubltt. "The  reason it 
has changed is that, if you don't use 
the whole organism you can't cause 
the disease, so you get away from the 
liability issues." 
"It's turned from being the 
Cinderella of the business to being 
very attractive," he says. "It's now 
one of the most profitable parts of 
the pharmaceutical industry:" 
Protcctlon from liability has also 
come from legislation, and the size of 
some trials has been scaled back if 
the protective levels of antibody arc 
known from an earlier vaccine (as is 
the case with AMs's hepatitis B 
vaccine). Axis is further protecting 
itself by drawing extensively on the 
expertise of academic ollaborators. 
It uses this expertise, for example, to 
identify the proteins or epitopes for 
use in vaccines. 
The promise to the developing world 
The dream of a vaccine-laden banana 
tree in every backyard is not going to 
happen - -  for starters there is the 
containment issue. Cubitt says the 
final vaccine "won't be fresh material, 
it will be a powdered formulation that 
can be stored at room temperature." 
I low the temperature stability will be 
achieved has not been disclosed but, 
he says, "we believe that our 
approaches will lead to temperature 
stability." 
Could this material be produced 
in the countries that need it most? 
"The  type of technology we are 
using is more related to food 
processing technology than 
pharmaceutical technolog3; because 
we are not aking out the food 
material or doing a purification," says 
Cubitt. "Theoretical ly this could be 
produced around the world, but we 
need to know that it is produced 
under pharmaceutical controls not 
agricuhural controls. These  are 
pharmaceutical products not 
agricultural products." 
In the final stages of production, 
edible vaccines may resemble the 
pharmaceuticals that they most 
certainly are. But if the vaccincs 
work, the wonder of their source will 
remain: protection from disease 
using only sunlight, dirt and water as 
the primary ingredients. 
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